RESEARCH MONOGRAPH · KDC-MN-133

Dulaglutide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

70/100

The weekly Fc-fusion GLP-1 that proved you could engineer the half-life problem away cleanly

Dulaglutide is GLP-1 fused to a modified IgG4 Fc fragment via a small linker. Eli Lilly's bet on antibody-derived half-life extension as the route to weekly dosing. The Fc handle gives you FcRn-mediated recycling and the structural size to avoid renal filtration, which together push the half-life out past 4 days. AWARD trial program showed the glycemic control and weight effects you'd expect for a weekly GLP-1, though the weight loss is on the lower end of the class (3 to 5 percent typically, less than semaglutide).

The mechanism is straightforward GLP-1R agonism, but the molecular engineering is the interesting part. Two GLP-1 molecules per Fc, so it's effectively bivalent. The Fc is engineered to be non-effector (the IgG4 backbone with additional mutations to suppress FcgammaR and complement binding) because you obviously dont want immune activation against a metabolic drug. As an example of intentional protein engineering for drug development its a textbook case.

What we like: stable molecule, well-characterized PK, weekly dosing without the C20 fatty acid acylation route that semaglutide uses. The structural engineering approach is conceptually clean and has translated to other Fc-fusion drugs (alefacept, etanercept historically). For research thats a tool to compare with the acylated GLP-1s and tirzepatide.

What we dont like: efficacy on weight is lower than semaglutide at the doses studied, which has put it in second-tier position commercially. The molecular size also means it doesnt cross into CNS spaces as readily as smaller GLP-1 agents, which may or may not matter for the satiety mechanism (the relevant GLP-1R populations are mostly accessible from circulation through circumventricular organs anyway).

Sourcing: Fc-fusion proteins are technically more demanding to produce than naked peptides. You need mammalian expression, proper folding, glycosylation control. Research-grade dulaglutide from reputable biologics suppliers is fine; the cheap end of the market is risky because incomplete or misfolded Fc fragments will read on SDS-PAGE but not have proper activity. Get binding assay data if you can.

Solid research tool. Underrated as a comparator molecule for studying GLP-1R biology.

Evidence: 88
Mechanism: 85
Reliability: 82
Safety: 80
Sourcing: 60
Value: 50
Signal: 60
Staying power: 55

Plain-language summary Intrigue 72 / 100

Dulaglutide, sold as Trulicity, is a once-weekly GLP-1 receptor agonist constructed as an Fc-fusion protein for extended half-life. FDA-approved for type 2 diabetes and cardiovascular risk reduction. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Weekly GLP-1 Fc fusion

A GLP-1 analog fused to human IgG4 Fc for weekly dosing, FDA-approved as Trulicity for T2DM.

Abstract

Dulaglutide (Trulicity; CAS 923950-08-7; molecular weight ~63000) is an IgG4-Fc fusion protein containing two modified GLP-1(7-37) sequences. The Fc fusion provides extended half-life of approximately 5 days through neonatal Fc receptor recycling, supporting a once-weekly subcutaneous administration interval. The compound was developed by Eli Lilly and approved by the FDA in 2014 for T2DM. Reported research dose ranges in the literature span roughly 0.75 to 4.5 mg subcutaneously. The cardiovascular outcomes program (REWIND) demonstrated MACE reduction in T2DM patients with cardiovascular risk factors.

Mechanism of action

GLP-1 receptor agonist fused to IgG4 Fc; weekly dosing through FcRn recycling.

Reported research dose ranges

Reported research dose ranges in the literature span roughly 0.75 to 4.5 mg subcutaneously.

References

Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-133

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Dulaglutide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs